Vaxcyte (PCVX)Officer sold ~$1.56M

~$1.56M

Approx. value · 18K sh @ $86.74

145K

Holds after · shares reported

Traded

Oct 5, 2026

Filed

Oct 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 16, 2026CongressDisclosed purchase of PCVX — reported range $1,001 - $15,000
2. Aug 31, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 31, 2026, Vaxcyte, Inc. (the “Company”) appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.”
3. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$128K)
4. Oct 5, 2026 · this disclosureInsider · Their largest sale since 2021Officer sold ~$1.56M of PCVX shares in the open market

What came next

1. Oct 5, 2026Insider · Their largest sale since 2024Officer sold ~$1.65M of PCVX shares in the open market
2. Oct 6, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vaxcyte

For Vaxcyte, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCVX page.

Other recent filings by Jim Wassil, EVP, Chief Scientific Ofc, COO

• SEC Form 4 at Vaxcyte (PCVX)Oct 3, 2026
• SEC Form 4 at Vaxcyte (PCVX)Oct 3, 2026
• SEC Form 4 at Vaxcyte (PCVX)Mar 4, 2025
• SEC Form 4 at Vaxcyte (PCVX)Mar 4, 2025
• SEC Form 4 at Vaxcyte (PCVX)Feb 5, 2025

The full history of Jim Wassil, EVP, Chief Scientific Ofc, COO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Vaxcyte

• SEC Form 4Oct 8, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• House Clerk periodic transaction reportSep 4, 2026

Everything OQRO holds on this company is on its PCVX page.